Since Fc-mediated enhancement of CD137 agonism has been implicated in the off-tumor toxicities of anti-CD137 antibodies, CD137 agonists with robust potency independent of Fc receptor crosslinking emerge as superior alternatives 34. Here, TNFRSF9 is linked to neoplasm.